Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of BMS-986165 in moderate to severe plaque psoriasis
CTR20200187Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Started Jul 2020; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20200187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200187.